Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine, carboplatin and trastuzumab in advanced HER2-positive breast cancer (phase 2)
2006-003994-28Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine, carboplatin and trastuzumab in HER2-enriched breast cancer (HER2+), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Activity of vinorelbine + carboplatin + trastuzumab. Started Jun 2007; status: completed.
02
Drugs
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on 2006-003994-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003994-28.